Concentra, Inc. Third Quarter 2026 Earnings Call - CONCENTRA GROUP HOLDINGS PARENT INC

Explicit Guidance:

• FY2026 Revenue: Raised to $2.36 billion – $2.38 billion (increased low end by $35M, high end by $5M).
• FY2026 Adjusted EBITDA: Lowered to $505 million – $510 million (decreased low end by $20M, high end by $15M).
• FY2026 Free Cash Flow: Unchanged range of $220 million – $240 million.
• FY2026 Capital Expenditures: Unchanged range of $70 million – $80 million.
• FY2027 Guidance: Formal guidance to be provided in early 2027; no definitive numbers released yet due to pending visibility into economic and reimbursement environments.
• Shareholder Returns: New $250 million share repurchase program authorized with no expiration; quarterly dividend declared at $0.625 per share, payable around December 4, 2026.

Business-Segment Outlook:

• Employer Services: Rate growth expected to remain consistent with long-term expectation of approximately 3%; Q3 growth (5.8% visits, 4% rate) attributed to strong hiring-related services (drug screens, physicals) in transportation, logistics, manufacturing, and construction.
• Workers' Compensation: No definitive outlook for rate growth due to unannounced state fee schedules; expected to remain materially consistent with long-term expectations absent significant shifts.
• Expansion Plan: 15 new centers expected to open in 2026 via acquisitions and de novo development; anticipated low double-digit de novo openings in 2027.
• New Markets: Exploring entry into New York via de novo or small bolt-on acquisition in early 2027 following regulatory fee schedule adjustments.
• On-Site Business: Fundamentals remain strong driven by employer cost management focus and sales pipeline; potential for incremental referrals from on-site to brick-and-mortar clinics where proximity allows, though currently immaterial.
• Organic Growth: Pivot (acquired business) now included in organic calculation, diluting growth rates slightly; core business growth remains strong.

Market and Competitive Outlook:

• Demand Trends: Broad-based growth across all six regions and end markets driven by favorable labor market conditions in blue-collar sectors.
• Market Share: Management expects to continue market share gains supported by improved retention (multi-year highs) and new business activity tracking ahead of 2025 levels.
• Pricing Strategy: Employer services rate increases (typically ~3%) communicated to employers in Q4 and effective January 1 annually; anticipated to align with historical norms.
• Fee Schedules: 20–25 states expected to release 2027 fee schedules in December (effective Jan 1); management awaiting full data set before finalizing outlook.
• Share Gains: Driven by sales execution, account management, technology enhancements, and operational efficiencies (turnaround times, patient satisfaction).

Macro / Industry Outlook:

• Labor Market: Continued growth in blue-collar employment supporting injury volumes; no signs of labor market deterioration.
• Economic Indicators: Employer services growth viewed as a leading indicator for future workers' compensation volumes (typically 1-2% historical growth vs. 5.8% recent pickup).
• Reshoring & Data Centers: Optimistic regarding manufacturing and construction growth (including data center build-outs) as tailwinds for employer services; currently viewed as broad-based rather than concentrated in specific industries.
• Inflation & Labor Costs: Wage inflation expected to remain around 3%; turnover stable or improving; no significant labor availability constraints anticipated for 2027.
• Political/Regulatory: No specific view on election impacts; monitoring policy but observing broad strength across geographies and industries regardless of political shift.
• Rates: Management expects aggregate rate growth to align with long-term algorithm (3%) barring state-level fee schedule deviations.

Strategic Initiatives:

• M&A Pipeline: Strong pipeline of "bolt-on" transactions progressing; disciplined evaluation of returns for both acquisitions and de novo development.
• Capital Allocation Priorities: 1) Accreted growth opportunities (organic and inorganic); 2) Debt reduction (target net leverage of 2.5x, currently 2.90x); 3) Share repurchases (elevated to 1B/1C priority).
• Operational Improvements: Continued rollout of technology enhancements to support center efficiency; leveraging national sales force to penetrate new markets (e.g., UPS, Amazon, FedEx) via corporate contacts.
• Separation Completion: Multi-year separation from Select Medical substantially complete; TSA expiration expected end of month.
• Capacity Additions: Completed 4 acquisitions in Minnesota; opened 3 de novos in Kansas City, Boise, and Daytona Beach; 2 additional centers opened post-quarter end; 1 more expected by year-end.

Risks and Headwinds to Outlook:

• State Fee Schedules: Uncertainty in state-specific workers' compensation fee schedule releases for 2027 could impact rate guidance.
• Macro Volatility: Potential shifts in economic conditions, though currently viewing trends as broad-based and positive.
• Mix Volatility: Quarterly revenue per visit fluctuations due to mix shifts between physicals and drug screens are expected to remain inconsistent and non-durable.
• Regulatory Delays: New York regulatory decisions and effective dates remain undefined, potentially delaying market entry.
• Guidance Caveats: Actual results may differ materially due to factors such as tax payments (OBBBA roll-off), working capital timing, and acquisition timing.

Management Tone on the Future:

• Confidence: High confidence in sustaining current margin levels (22.5% adjusted EBITDA margin) and operating performance; view business as entering next chapter from "considerable strength."
• Guidance Stance: Cautious but optimistic on 2027; explicitly stating it is "too early" for definitive rate outlooks but expecting consistency with long-term averages.
• Strategic View: Management believes they are "in the middle" of a growth cycle exceeding long-term averages (low single-digit algorithm) due to a confluence of factors (operational execution, acquisition, labor market, reshoring) and expects to sustain momentum.
• Margin Outlook: Confidence in sustaining 2026 margin expansion levels, though acknowledging year-over-year margin growth may not match the 2026 spike due to lapping separation costs; medium-term expansion opportunities remain via center investments and efficiencies.
• Capital Discipline: Emphasis on disciplined capital allocation, prioritizing accretive growth over speculative expansion, with flexibility to execute buybacks only after deleveraging toward 2.5x target.

Miscellaneous:

• Credit Metrics: Net leverage ratio of 2.90x (down from higher levels); S&P rating upgraded from BB- to BB (Aug 2026); Moody's outlook revised from Stable to Positive (Oct 2026).
• Debt Paydown: Repaid $52.4 million in Q3 ($50M discretionary prepayment); total debt balance $1.52 billion.
• Acquisition Accounting: Pivot acquisition anniversary included in organic growth calculation, causing slight moderation in reported organic growth rates vs. Q2.